LGND
Ligand Pharmaceuticals Incorporated
NASDAQ · USHealthcareBiotechnology
$293.99-3.10%
Price as of Jul 20, 2026
LGND valuation
Ligand Pharmaceuticals Incorporated valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- 61.73x
- P/E 2026E
- 35.06x
- P/E 2027E
- 30.94x
- P/E 2028E
- 28.75x
- P/S forward
- 41.15x
Trailing multiples
- P/E TTM
- 37.50x
- PEG TTM
- —
- Price / book
- 5.91x
- Price / sales
- 21.47x
- Price / cash flow
- 47.74x
Enterprise value
- Enterprise value
- $5.6B
- EV / sales
- 20.27x
- EV / EBITDA
- 25.04x
- EV / EBIT
- 55.21x
- Market cap
- $5.9B
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.